Wednesday, July 8, 2026

Patent intelligence · US

US 8299173

Method involving 1-benzotriazolyl carbonate esters of polymers

granted A61KA61K31/7088A61K47/58A61K47/60
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 6
Applicant portfolio 423
Patent details — US 8299173
Jurisdiction
US
Status
granted
Grant date
Oct 30, 2012
Expiration
Oct 25, 2032
Claims
7
CPC classes
A61K, A61K31/7088, A61K47/58, A61K47/60
View on Google Patents ↗

Quick answer

US 8299173 (Method involving 1-benzotriazolyl carbonate esters of polymers) is held by Nektar Therapeutics. Status: granted. Granted Oct 30, 2012. Expires Oct 25, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
7
CPC classes
A61K, A61K31/7088, A61K47/58, A61K47/60, A61K47/6901, A61P

More from Nektar Therapeutics

Related pharmaceutical patents in our USPTO index.

  1. US 12324828

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Nektar Therapeutics · Expires Jun 5, 2045

    granted
  2. US 12325708

    Adenosine 2 receptor antagonists

    Nektar Therapeutics · Expires Jun 5, 2045

    granted
  3. US 12247059

    Conjugates of an IL-2 moiety and a polymer

    Nektar Therapeutics · Expires Mar 6, 2045

    granted
  4. US 12233104

    Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

    Nektar Therapeutics · Expires Feb 20, 2045

    granted
  5. US 12214045

    Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

    Nektar Therapeutics · Expires Jan 30, 2045

    granted
  6. US 12054553

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Expires Aug 1, 2044

    granted
  7. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics · Expires Jul 11, 2044

    granted
  8. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Expires Jul 4, 2044

    granted

Frequently asked questions

What is US patent 8299173?

US 8299173 (Method involving 1-benzotriazolyl carbonate esters of polymers) is held by Nektar Therapeutics. Status: granted. Granted Oct 30, 2012. Expires Oct 25, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8299173?

Nektar Therapeutics is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 423 pharmaceutical patents for this assignee.

When does US 8299173 expire?

Our index shows an expiration date of Oct 25, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.